Tagged with tech

China Jun Liu, CEO & Executive Board Director of BioDlink, defines and explores the company’s strategic focus on antibody drug conjugates (ADCs), their global expansion plans, and role as a leading CDMO. Liu emphasises the balance of quality and cost efficiency, stating, “Our mission is to deliver exceptional value, ensuring we…

China EpimAb Biotherapeutics’ Chengbin Wu explains why the expansion of bispecifics into solid tumors and autoimmune diseases marks a major therapeutic turning point. He outlines how, through rational antibody engineering and unique molecule formats, EpimAb has differentiated itself with safer, more effective therapies than its competitors, as well as how the…

Puerto Rico Dr. Eduardo Nicolau shares his journey from being a professor of chemistry to becoming Executive Director of the MSRC in 2021. His leadership focuses on financial stability, creating a biotech incubator, and establishing key partnerships with the industry, including a significant collaboration with the biotechnology company CytoImmune Therapeutics for cancer…

China A roundup of some of the biggest stories coming out of China’s pharma industry, including the new drugs added to the country’s national health insurance with AstraZeneca’s breast cancer blockbuster, Enhertu, among them; the launch of Novo’s Wegovy in China; Eli Lilly’s obesity partnership with Hong Kong-listed Laekna; Merck’s cancer…

Mexico Victor Matos, Senior Commercial Director at Johnson & Johnson MedTech in Mexico, shares insights about his first days as a Managing Director, highlighting the importance of connecting the company’s objectives with Mexico’s diverse healthcare system. He emphasises J&J’s significant local footprint, with major commercial and manufacturing operations including a key…

Switzerland Matteo Boggi, General Manager of Fresenius Kabi Switzerland, shares insights into the company’s pivotal role in supporting healthcare professionals as well as critically and chronically ill patients across Switzerland. Boggi highlights Fresenius Kabi’s extensive portfolio in nutrition, medical devices, generic drugs, and biosimilars, while discussing the company’s innovative strategies and…

Switzerland Dominik Escher, Managing Partner of Pureos Bioventures explores the firm’s strategic focus on drug development, particularly in biologics and antibody-based therapeutics. With a keen emphasis on the Swiss biotech ecosystem, Escher discusses the firm’s investment approach and its commitment to fostering innovation in Europe and beyond.   Swiss biotech stands…

Switzerland Emanuele Ostuni, CEO of ARTBIO, delves into the company’s innovative approach to radioligand therapies, focusing on its potential to replace chemotherapy and provide more effective treatment options for patients. Ostuni emphasizes the company’s commitment to precision oncology, with a strong team spread across Switzerland, Norway, USA, and the UK.  …

Puerto Rico Long recognized for its strengths in manufacturing and distribution, Puerto Rico is looking to capitalize on its positive attributes and position itself as a centre for innovation. While important tax incentives have provided stimulus for R&D, the US territory is also working on building a strong local ecosystem, developing and…

Mexico Patricia Nakagawa, Managing Director of Karl Storz, Mexico Caribbean and Central America, explains the German family-owned MedTech’s ongoing evolution towards a more corporate structure and the new hub status she has helped to usher in for the regional affiliate. Nakagawa also highlights the company’s integrated operating room (OR) solution, as…

Switzerland Georg Pirmin Meyer, SVP and Head of International at Blueprint Medicines, shares insights into the company’s journey from a promising startup to a fast-scaling biotech leader focused on allergy/inflammation and haematology/oncology. Meyer discusses Blueprint’s innovative approach to international expansion, patient-centric strategy, and ambitious plans for growth in new markets. He…

Switzerland Lars Nieba PhD, CEO of Engimmune, shares insights into the company’s innovative approach to T-cell therapies and its strategic direction as it prepares for its Series A funding round. Nieba discusses the promising therapeutic areas Engimmune is targeting—particularly liver cancer and immunology—and the company’s unique technology that harnesses soluble T-cell…